Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549× 106/L CD4 cell counts: a randomized …
ContextDespite enormous improvements achieved through the use of antiretroviral
therapies (ARTs), the risk for eventual human immunodeficiency virus (HIV) disease
progression remains high. Agents that enhance the immunologic mechanism for viral
recognition might reduce disease progression. ObjectiveTo determine whether the addition
of HIV-1 Immunogen would confer added clinical efficacy to that achievable by ARTs.
Design and SettingMulticenter, double-blind, placebo-controlled, randomized trial beginning …
therapies (ARTs), the risk for eventual human immunodeficiency virus (HIV) disease
progression remains high. Agents that enhance the immunologic mechanism for viral
recognition might reduce disease progression. ObjectiveTo determine whether the addition
of HIV-1 Immunogen would confer added clinical efficacy to that achievable by ARTs.
Design and SettingMulticenter, double-blind, placebo-controlled, randomized trial beginning …